If the Supreme Court upholds a broad view of pre-emption, restraining state courts from second-guessing safety balances performed at the FDA level, it will be advancing the cause of rational drug regulation, argues Tomas J. Philipson, who's a former senior economic adviser to the FDA commissioner and chairman of Project FDA at the Manhattan Institute.